Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LANCE A SLOAN

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1588665228
CMS profile
344281
Location
LUFKIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$456,967.60

672 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 13 of 14; records 601–650 of 672 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LANCE A SLOAN

NPI 1588665228 · CMS profile ID 344281

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

LUFKIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 13 of 14; records 601–650 of 672 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588665228?year=2019&recipient=provider&page=13#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LANCE A SLOAN, NPI 1588665228, CMS profile ID 344281. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 14; records 601–650 of 672 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588665228?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LANCE A SLOAN, NPI 1588665228, CMS profile ID 344281. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 14; records 601–650 of 672 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588665228?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LANCE A SLOAN, NPI 1588665228, CMS profile ID 344281, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 13 of 14; records 601–650 of 672 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1588665228?year=2019&recipient=provider&page=13#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

672 matching records · $456,967.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 672 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 601–650 of 672.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $13.3602/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685977517 CMS
AstraZeneca Pharmaceuticals LP $394.2002/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685461152 CMS
AstraZeneca Pharmaceuticals LP $2,052.5402/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685859499 CMS
Janssen Pharmaceuticals, Inc $5.0802/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659300225 CMS
AstraZeneca Pharmaceuticals LP $4,300.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685076697 CMS
AstraZeneca Pharmaceuticals LP $4,300.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685198173 CMS
AstraZeneca Pharmaceuticals LP $1,600.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685260641 CMS
AstraZeneca Pharmaceuticals LP $1,600.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685428855 CMS
AstraZeneca Pharmaceuticals LP $1,600.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685465291 CMS
AstraZeneca Pharmaceuticals LP $4,300.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685889467 CMS
AstraZeneca Pharmaceuticals LP $1,600.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685895533 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.0002/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700414603 CMS
Merck Sharp & Dohme Corporation $3,500.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695251119 CMS
Merck Sharp & Dohme Corporation $150.0002/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695251121 CMS
Merck Sharp & Dohme Corporation $25.0002/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695258593 CMS
Merck Sharp & Dohme Corporation $3,500.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695259757 CMS
Merck Sharp & Dohme Corporation $3,500.0002/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695226931 CMS
Merck Sharp & Dohme Corporation $25.0002/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695226935 CMS
Lilly USA, LLC $675.0001/31/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657977649 CMS
Merck Sharp & Dohme Corporation $12.2301/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695226881 CMS
Merck Sharp & Dohme Corporation $560.5201/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695350529 CMS
Merck Sharp & Dohme Corporation $110.1901/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695761969 CMS
AstraZeneca Pharmaceuticals LP $96.6901/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685092533 CMS
AstraZeneca Pharmaceuticals LP $154.2801/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685354849 CMS
AstraZeneca Pharmaceuticals LP $170.5801/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685395027 CMS
AstraZeneca Pharmaceuticals LP $185.5801/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685647141 CMS
Merck Sharp & Dohme Corporation $525.2601/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695245735 CMS
Merck Sharp & Dohme Corporation $1,496.0001/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695251117 CMS
Merck Sharp & Dohme Corporation $134.7201/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695251123 CMS
Merck Sharp & Dohme Corporation $108.6801/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695760879 CMS
Radius Health, Inc. $16.2201/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683955979 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $144.0201/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700414569 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $229.3701/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700414585 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $330.4901/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700414619 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $46.0101/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700414625 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $31.1201/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700414709 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $59.8101/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700414711 CMS
AstraZeneca Pharmaceuticals LP $252.2201/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685127147 CMS
AstraZeneca Pharmaceuticals LP $12.1101/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685298483 CMS
AstraZeneca Pharmaceuticals LP $112.6601/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685577789 CMS
AstraZeneca Pharmaceuticals LP $17.6401/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685650715 CMS
AstraZeneca Pharmaceuticals LP $112.3701/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685763219 CMS
AstraZeneca Pharmaceuticals LP $129.7301/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685231133 CMS
AstraZeneca Pharmaceuticals LP $45.9401/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685541129 CMS
AstraZeneca Pharmaceuticals LP $25.1601/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685558245 CMS
AstraZeneca Pharmaceuticals LP $239.6601/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685605139 CMS
AstraZeneca Pharmaceuticals LP $60.8401/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685692743 CMS
AstraZeneca Pharmaceuticals LP $1,655.3101/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685964827 CMS
AstraZeneca Pharmaceuticals LP $19.3501/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685988769 CMS
Janssen Pharmaceuticals, Inc $14.2601/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659300221 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $456,967.60 672
PY2020 $172,406.57 321
PY2021 $202,742.45 324
PY2022 $127,705.67 252
PY2023 $186,189.02 334
PY2024 $360,442.63 449
PY2025 $235,847.87 384

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $984.91 7
PY2025 Principal investigator $383,385.48 20
PY2024 Recipient $8,938.00 1
PY2024 Principal investigator $227,961.71 9
PY2023 Recipient $1,955.07 10
PY2023 Principal investigator $102,955.18 10
PY2022 Recipient $3,287.53 7
PY2022 Principal investigator $178,346.98 23
PY2021 Principal investigator $369,322.20 119
PY2020 Principal investigator $242,951.84 38
PY2019 Recipient $16,705.78 15
PY2019 Principal investigator $413,289.60 45

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $10,020.00 12/17/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220780462
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $40,061.76 11/30/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220998989
Principal investigator 1 Boehringer Ingelheim International GmbH $5,065.00 11/17/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220780460
Principal investigator 1 Boehringer Ingelheim International GmbH $14,645.00 10/22/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220780458
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $40,061.76 09/30/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220998987
Principal investigator 1 Boehringer Ingelheim International GmbH $17,905.00 09/08/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220780456
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $40,061.76 08/31/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220998985
Principal investigator 1 Boehringer Ingelheim International GmbH $6,360.00 08/18/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220780454
Principal investigator 1 Boehringer Ingelheim International GmbH $13,435.00 07/07/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220780452
Principal investigator 1 Boehringer Ingelheim International GmbH $26,960.00 06/09/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220780448
Principal investigator 1 Boehringer Ingelheim International GmbH $8,170.00 05/12/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220780450
Recipient Corcept Therapeutics $57.59 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214165123
Recipient Corcept Therapeutics $76.44 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214165132
Recipient Corcept Therapeutics $98.62 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214165136
Recipient Corcept Therapeutics $32.67 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214165140
Recipient Corcept Therapeutics $71.74 05/02/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214165144
Recipient Corcept Therapeutics $461.96 05/01/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214165118
Recipient Corcept Therapeutics $185.89 05/01/2025 Covered Recipient Physician COR311 No dispute reported 06/30/2026 1214165128
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $13,353.92 04/30/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220998983
Principal investigator 1 Boehringer Ingelheim International GmbH $15,290.00 04/09/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220780446
Principal investigator 1 Boehringer Ingelheim International GmbH $17,670.00 03/12/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220780444
Principal investigator 1 Eli Lilly and Company $289.00 02/25/2025 Non-covered Recipient Entity
LANCE SLOAN,
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187884346
Principal investigator 1 Amgen Inc. $31,904.48 02/21/2025 Non-covered Recipient Entity
TEXAS INSTITUTE FOR KIDNEY AND ENDOCRINE DISORDERS
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246649223
Principal investigator 1 Boehringer Ingelheim International GmbH $6,540.00 02/14/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220780442
Principal investigator 1 Eli Lilly and Company $24,677.00 01/21/2025 Non-covered Recipient Entity
LANCE SLOAN,
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187885344
Principal investigator 1 Eli Lilly and Company $41,105.80 01/21/2025 Non-covered Recipient Entity
LANCE SLOAN,
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187885346
Principal investigator 1 Boehringer Ingelheim International GmbH $9,810.00 01/13/2025 Non-covered Recipient Entity
Texas Institute For Kidney And Endocrine Disorders
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220780440